Threepipe wins pain-relief gel account

Threepipe has been appointed by the medical science company Pro Bono Bio to raise awareness of its new drug-free pain relieving gel, FLEXISEQ.

FLEXISEQ: Aimed primarily at the UK's nine million sufferers of osteoarthritis
FLEXISEQ: Aimed primarily at the UK's nine million sufferers of osteoarthritis
The agency, which won the business following a competitive pitch against two others, will highlight the lifestyle benefits of using FLEXISEQ, which can be used by people who suffer from osteoarthritis.

Jim Hawker, co-founder of Threepipe, said: "It’s not very often that a genuinely scientific breakthrough, non-prescription, medical product comes to the market and it’s exciting to be on board to help the brand reach its full potential in the UK."

Threepipe’s press office work will focus on reaching the UK’s nine million osteoarthritis sufferers via national and lifestyle media as well as developing creative campaigns to run at key times of the year.

The agency will also develop digitally led integrated campaigns across earned, owned and paid media as well as overseeing the brand’s social media channels.

Another focus for Threepipe will be to build on the brand’s growing use by professional athletes, including those from the Saracens rugby team, who use the gel to manage pain.

Pro Bono Bio said it was Threepipe’s ability to run an effective press office as well as maximising the digital opportunities around the brand that won it the business.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in